Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture
- Conditions
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2012-04-24
- Lead Sponsor
- Beijing Army General Hospital
- Target Recruit Count
- 800
- Registration Number
- NCT01583660
- Locations
- 🇨🇳
Beijing Army General Hospital, Beijing, Beijing, China
A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 547
- Registration Number
- NCT01572675
The Pharmacokinetic Interaction Between Celecoxib and Rebamipide
- Conditions
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01549743
- Locations
- 🇰🇷
The Korea Univertisy Anam Hospital, Seoul, Korea, Republic of
Study of Indomethacin Capsules to Treat Pain Following Bunionectomy
- Conditions
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Iroko Pharmaceuticals, LLC
- Target Recruit Count
- 462
- Registration Number
- NCT01543685
- Locations
- 🇺🇸
Chesapeake Research Group, LLC, Pasadena, Maryland, United States
🇺🇸Premier Research Group Limited, Salt Lake City, Utah, United States
Efficacy and Safety of Shinbaro Capsule
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 198
- Registration Number
- NCT01535417
Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2012-01-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT01503385
- Locations
- 🇨🇳
Jun Liang, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 100
- Registration Number
- NCT01479829
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Study of Diclofenac Capsules to Treat Pain Following Bunionectomy
- Conditions
- Interventions
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Iroko Pharmaceuticals, LLC
- Target Recruit Count
- 428
- Registration Number
- NCT01462435
- Locations
- 🇺🇸
Chesapeake Research Group, LLC, Pasadena, Maryland, United States
🇺🇸Premier Research Group Limited, Salt Lake City, Utah, United States
A Study of LY3031207 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT01449630
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT01425476
- Locations
- 🇺🇸
University of North Dakota, Grand Forks, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.